General Urology
12 cases on 5-alpha-reductase inhibitor and alpha-blocker selection for BPH, persistent post-finasteride sexual dysfunction, storage-symptom drug-class choice, PSA interpretation on 5-ARI therapy, combination BPH/ED treatment, medication timelines in refractory urinary retention, post-surgical medication reconciliation, chronic prostatitis/CPPS phenotyping, antibiotic selection with lifestyle risk factors, neuromodulator trials before surgery, anticoagulation management with new hematuria, and testosterone therapy in untreated LUTS — choose a case below to open its full multi-voice debate.
Two men on tamsulosin for benign prostatic hyperplasia, both being considered for an added 5-alpha-reductase inhibitor. The drug is the same; the argument for using it is not — one man's numbers make the case, the other's don't quite, and he has already told the team what that should mean.
A man's sexual side effects persisted eight months after he stopped finasteride. The team isn't being asked to prove what caused it — they're being asked how to counsel him honestly about a risk that is officially labeled and genuinely unresolved.
A man's urge incontinence isn't controlled on an alpha-blocker alone, and his post-void residual sits in the upper reach of what the trial evidence for adding an anticholinergic actually studied. The debate isn't really about that edge — it's about whether a different drug class makes the edge irrelevant.
His PSA doubled while on finasteride — a number the standard correction rule turns into a concerning value, built from a population average nobody has validated against him specifically.
A treatment-naive man has both bothersome urinary symptoms and erectile dysfunction. One drug is labeled for both. The question is whether treating both problems adequately beats treating one problem well.
A man too fragile for surgery has failed three trials of void. Before anyone accepts catheter dependence, the question is whether his medical therapy has actually run its full course — or whether the clock on it never really started.
A surgery resolved his obstruction three months ago. Nobody has revisited the two medications started before it, and one of them may be the actual reason he's dizzy every time he stands up.
His cultures are negative and the standard first-line combination has already been tested against placebo and lost. The debate is whether to keep reaching for it out of habit or build a plan around what actually seems to be driving his pain.
Two oral antibiotics both cover his organism. One reaches the prostate better; the other avoids a real risk specific to how he spends his weekends. The choice isn't as simple as picking the drug with the best tissue penetration on paper.
His workup is negative, NSAIDs haven't helped, and surgery is on the table. The disagreement is whether a mechanistically different oral option deserves a real trial before anyone reaches for an operation that can't be undone.
A mechanical heart valve makes stopping anticoagulation dangerous. New gross hematuria at a therapeutic INR makes ignoring it dangerous too. The disagreement is over how much room exists to do both at once.
Newer evidence has quieted the old fear that testosterone worsens urinary symptoms. That evidence was gathered in men whose LUTS were mild or already treated — not a man with a symptom score of 22 who has never been treated at all.